Anti-miRNA (AM) therapeutic approaches seem particularly attractive since alteration in miRNA abundance appears to occur at relative early “initiator” or “propagatory” stages of the AD process while NF-kB inhibition may have too many unwanted off-target effects (Figure 1). This evidence concerns the gene NFKB1 and Alzheimer disease.